Mallinckrodt (NYSE:MNK) said today that it enrolled the 1st patient in the pivotal Phase III trial of its StrataGraft skin tissue graft.
The study is slated to include patients with 3% to 49% total body surface area of severe thermal burns.
Researchers intend to evaluate outcomes including the area of StrataGraft treatment site that requires a subsequent autograft compared to the control site and the proportion of participants that achieve durable wound closure of the treatment site without autograft placement.
Get the full story at our sister site, Drug Delivery Business News.